医药板块全线走弱，医疗创新ETF(516820.SH)获资金积极申购

Group 1 - The pharmaceutical sector is experiencing a decline, with the Medical Innovation ETF (516820.SH) down by 0.76% [1] - Among the constituent stocks, Xingqi Eye Medicine (300573) leads with a 6.10% increase, while Kanghong Pharmaceutical (002773) sees the largest drop at 4.12% [1] - The Medical Innovation ETF has seen continuous net inflows over the past three days, totaling 52.86 million yuan, with a peak single-day inflow of 35.09 million yuan [1] Group 2 - Market dynamics are shifting, with funds moving from high-valued sectors to reasonably valued areas, indicating a potential expansion of the pharmaceutical market from innovative drugs to lower-valued medical devices [2] - Core assets in the medical sector are showing signs of recovery, with many top constituent stocks trading below the historical 20th percentile, highlighting a significant margin of safety [2] - Weak economic and employment data in the U.S. may accelerate the Federal Reserve's rate cuts, enhancing global liquidity and benefiting technology stocks, presenting a good opportunity for investors to position themselves in the Medical Innovation ETF (516820) [2]